{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:\n\n* Complete Response (CR): disappearance of all target lesions;\n* Partial Response (PR) 30% decrease in sum of longest diameter of target lesions;\n* Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions;\n* Stable Disease (SD): small changes that do not meet above criteria.\n\nOverall tumor response is the total number of CR and PRs.","groups":[{"description":"Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma","id":"OG000","title":"Dasatinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration of study until progression (up to 3 years)","title":"Number of Participants With Overall Tumor Response","type":"SECONDARY","unitOfMeasure":"participants"}